Search Results 31-40 of 27689 for %EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDop%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BD%EF%BF%BDr%EF%BF%BD%EF%BF%BD%EF%BF%BD%3Aza33%EF%BF%BD%EF%BF%BD%EF%BF%BD
... EF was normal, patients had an estimated fivefold increased risk of developing a low EF in the future. "This suggests that the network may reveal silent ...
Izzy M, Addissie BD ... EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE ... Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.Hepatology.
... EF. Integrating Infectious Diseases and Preventive Medicine Specialties Into 1 Division: Experience of an Academic Medical Center. Mayo Clin Proc. 2023 Feb ...
The purpose of this study is to test if a reduction of hemoglobin leads to subclinical cardiac dysfunction in patients with known cardiovascular disease.
Contact Us · Patient & Visitor Guide. Health Library. Diseases & Conditions · Symptoms · Tests & Procedures · Drugs & Supplements · Healthy Lifestyle.
EF ≥ 40%; and; Cardiac imaging from any time point showing increased LV wall thickness as defined by an end-diastolic left ventricular septal or posterior ...
... EF, Rajalingam R. Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory ...
The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make your tax-deductible gift and be a part of the cutting-edge research and care that's changing medicine.